Older Non-Small Cell Lung Cancer Patients (/= 70 Years of Age) Treated with FirstLine MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Study of Pembrolizumab Alone or in Combination with Chemotherapy in Older Patients with Non-Small Cell Lung Cancer
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAT8805
U.S. Govt. ID: NCT04533451
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This trial studies the side effects of pembrolizumab with or without chemotherapy in treating patients with non-small cell lung cancer that has come back and has spread to other places in the body. Pembrolizumab is an immunotherapy that may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy works in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with or without chemotherapy may shrink the tumor in older patients with non-small cell lung cancer.
This study is closed
Catherine Shu, MD
Do You Qualify?
Are you 70 years of age or older? Yes No
Have you been diagnosed with non-small cell lung cancer that has spread to other parts of your body? Yes No
Are you able to make regularly scheduled visits to the clinic for treatment and examinations? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator